Fidelity International’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.66M | Buy |
21,623
+11,820
| +121% | +$5.51M | 0.01% | 593 |
|
|
2025
Q4 | $4.44M | Buy |
9,803
+1,097
| +13% | +$473K | ﹤0.01% | 677 |
|
|
2025
Q3 | $3.41M | Sell |
8,706
-12,408
| -59% | -$5.19M | ﹤0.01% | 682 |
|
|
2025
Q2 | $9.4M | Sell |
21,114
-72,294
| -77% | -$33.3M | 0.01% | 552 |
|
|
2025
Q1 | $45.3M | Buy |
93,408
+135
| +0.1% | +$62.9K | 0.04% | 325 |
|
|
2024
Q4 | $37.6M | Buy |
93,273
+86,242
| +1,227% | +$40M | 0.04% | 364 |
|
|
2024
Q3 | $3.27M | Sell |
7,031
-674
| -9% | -$324K | ﹤0.01% | 662 |
|
|
2024
Q2 | $3.61M | Buy |
7,705
+7,020
| +1,025% | +$3.05M | ﹤0.01% | 635 |
|
|
2024
Q1 | $286K | Buy |
685
+3
| +0.4% | +$1.27K | ﹤0.01% | 787 |
|
|
2023
Q4 | $277K | Buy |
+682
| New | +$252K | ﹤0.01% | 757 |
|
|
2023
Q3 | – | Sell |
-47,037
| Closed | -$16.6M | – | 853 |
|
|
2023
Q2 | $16.6M | Sell |
47,037
-901
| -2% | -$304K | 0.02% | 429 |
|
|
2023
Q1 | $15.1M | Sell |
47,938
-167,736
| -78% | -$50.3M | 0.02% | 427 |
|
|
2022
Q4 | $62.3M | Sell |
215,674
-34,019
| -14% | -$10.4M | 0.07% | 267 |
|
|
2022
Q3 | $72.3M | Buy |
249,693
+2,140
| +0.9% | +$616K | 0.09% | 229 |
|
|
2022
Q2 | $69.8M | Buy |
247,553
+105,668
| +74% | +$28.3M | 0.08% | 239 |
|
|
2022
Q1 | $37M | Buy |
141,885
+137,222
| +2,943% | +$32.6M | 0.04% | 340 |
|
|
2021
Q4 | $1.02M | Buy |
4,663
+3,952
| +556% | +$768K | ﹤0.01% | 735 |
|
|
2021
Q3 | $129K | Sell |
711
-114,250
| -99% | -$22.3M | ﹤0.01% | 792 |
|
|
2021
Q2 | $23.2M | Sell |
114,961
-48,928
| -30% | -$10.2M | 0.02% | 434 |
|
|
2021
Q1 | $35.2M | Buy |
163,889
+163,804
| +192,711% | +$36M | 0.04% | 339 |
|
|
2020
Q4 | $20K | Sell |
85
-88,400
| -100% | -$20.3M | ﹤0.01% | 791 |
|
|
2020
Q3 | $24.1M | Sell |
88,485
-52,485
| -37% | -$14.5M | 0.03% | 368 |
|
|
2020
Q2 | $40.9M | Sell |
140,970
-97,141
| -41% | -$26.3M | 0.06% | 280 |
|
|
2020
Q1 | $56.7M | Buy |
238,111
+194,406
| +445% | +$44.6M | 0.09% | 213 |
|
|
2019
Q4 | $9.57M | Buy |
43,705
+43,699
| +728,317% | +$8.84M | 0.01% | 509 |
|
|
2019
Q3 | $1K | Buy |
6
+1
| +20% | +$177 | ﹤0.01% | 868 |
|
|
2019
Q2 | $1K | Sell |
5
-1
| -17% | -$175 | ﹤0.01% | 873 |
|
|
2019
Q1 | $1K | Buy |
6
+1
| +20% | +$185 | ﹤0.01% | 844 |
|
|
2018
Q4 | $1K | Hold |
5
| – | – | ﹤0.01% | 832 |
|
|
2018
Q3 | $1K | Buy |
+5
| New | +$890 | ﹤0.01% | 895 |
|
|
2017
Q3 | – | Sell |
-163,316
| Closed | -$21M | – | 523 |
|
|
2017
Q2 | $21M | Sell |
163,316
-137,392
| -46% | -$16.5M | 0.06% | 233 |
|
|
2017
Q1 | $32.9M | Buy |
300,708
+183,655
| +157% | +$16.2M | 0.09% | 192 |
|
|
2016
Q4 | $8.62M | Buy |
+117,053
| New | +$9.52M | 0.03% | 348 |
|
|
2014
Q1 | – | Sell |
-56,921
| Closed | -$4.23M | – | 645 |
|
|
2013
Q4 | $4.23M | Sell |
56,921
-241,979
| -81% | -$16.9M | 0.02% | 401 |
|
|
2013
Q3 | $22.7M | Sell |
298,900
-6,000
| -2% | -$477K | 0.11% | 192 |
|
|
2013
Q2 | $24.4M | Buy |
+304,900
| New | +$22.5M | 0.14% | 174 |
|
Other funds holding VRTX
VCM
VPM
Fidelity International's VRTX Position: Q1 2026 in Review
Fidelity International increased its Vertex Pharmaceuticals (VRTX) stake by 121% in Q1 2026, buying an estimated $5.51M and bringing the position to 21,623 shares worth $9.66M. The position accounts for 0.01% of the portfolio, ranked #593.
Fidelity International first reported a position in VRTX in Q2 2013 and has held it in 36 quarters since. The position peaked at $72.3M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Fidelity International held 21,623 shares of Vertex Pharmaceuticals worth $9.66M as of Q1 2026.
- Fidelity International bought 11,820 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.51M.
- Vertex Pharmaceuticals made up 0.01% of Fidelity International's portfolio in Q1 2026, its #593 holding.
- Fidelity International first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
- Fidelity International's Vertex Pharmaceuticals position peaked at $72.3M in Q3 2022.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.